Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.

Raccontata dabenzinga.com